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Introduction 
Hemophilia B is a rare X-linked recessive condition with an incidence of 1 in 30,000 
male births that results in factor IX deficiency.
1
 Recent reports have demonstrated that 
cardiac surgery can be safely performed in hemophiliacs, although patients with known 
hemophilia generally receive prophylactic doses of factor replacement.
2-4
 This case 
conference presents and discusses an unusual case of coronary artery bypass grafting 
(CABG)  in a patient with unknown hemophilia B wherein no prophylaxis was 
administered due to the lack of a comprehensive diagnosis. 
Case Presentation 
A 68-year-old man with a history of hypertension and hyperlipidemia presented to the 
hospital with an acute coronary syndrome.  He was medically managed and referred for 
left-heart catheterization that showed severe 3-vessel coronary artery disease. The patient 
was referred for elective CABG. The remaining history and physical exam were 
unremarkable.  There was no history of a bleeding disorder.  On the day of surgery, the 
complete blood count and coagulation tests were within normal limits, except for a partial 
thromboplastin time in the high normal range. 
 After placement of an arterial line, general endotracheal anesthesia was induced 
uneventfully. A pulmonary artery catheter and transesophageal echocardiography probe 
were subsequently placed without difficulty. The echocardiographic exam showed 
normal left ventricular function, mildly reduced right ventricular systolic function, and no 
significant valvular abnormalities. The baseline activated clotting time was 131 seconds. 
 After surgical incision, the surgeons noted more bleeding than usual, but this was 
attributed to recent clopidogrel therapy with residual intraoperative effects. After 
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dissection of both internal mammary arteries and harvesting of saphenous vein, systemic 
heparinization proceeded with a resultant activated clotting time greater than 1000 
seconds. Cardiopulmonary bypass was initiated uneventfully.  The patient underwent 
CABG with a pump time of 70 minutes.  The separation from cardiopulmonary bypass 
was without difficulty. The echocardiographic examination revealed no new findings.  
Protamine reversal proceeded with prompt return of the activated clotting time to 
baseline.    
 When hemostasis was thought to be reasonable, the chest was closed with sternal 
wires. After chest closure, however, the rate of bleeding appeared to increase with an 
extrapolated rate of 600mL per hour.  Given the high rate of bleeding, the chest was 
reopened, but no surgical source of bleeding was found. Shortly thereafter, the results of 
laboratory testing revealed a significantly elevated partial thromboplastin time, and 
thrombocytopenia.  Despite additional protamine, and ongoing titrated transfusion of 
platelets, fresh frozen plasma and cryoprecipitate, there was limited resolution of the 
coagulopathy.  While the resuscitation continued, the family was updated about the 
progress of the case – at this time, the family reported a history of factor IX deficiency.  
Factor IX levels were immediately drawn to confirm the diagnosis, and hematology was 
consulted for further evaluation and recommendations for management. 
 While awaiting both the factor IX level and recombinant factor IX therapy, an 
additional titrated transfusion of fresh frozen plasma was continued to treat the 
coagulopathy. By the time the recombinant factor IX was ready, the bleeding had slowed 
down and the factor IX level was still pending. The team decision was then reached to 
continue resuscitation in the intensive care unit, given that there were no sources of 
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bleeding that required surgical intervention.  Shortly after admission to the intensive care 
unit, the intraoperative factor IX level was reported at 24% of normal. Since the 
mediastinal bleeding had begun to worsen, recombinant factor IX was then administered 
as recommended by the hematology team. The hematology consultation was continued to 
guide the daily infusions of factor IX during the postoperative course (refer to Figure 1).  
The mediastinal coagulopathy resolved and surgical exploration was not required. 
 After tracheal extubation, the patient was questioned about prior bleeding 
episodes. He denied any previous problems with bleeding. Although he was aware of a 
family history of hemophilia, he had previously undergone dental extractions and nasal 
septoplastly without bleeding complications.  He was eventually discharged home on a 
course of intravenous recombinant factor IX. A follow-up factor IX level after 
completion of therapy was 15%, consistent with mild hemophilia B (refer to Figure 1). 
Case Discussion 
Hemophilia B is a rare hematologic disorder with varying deficiencies in factor IX. Its 
severity is classified according to factor IX plasma levels as a percentage of normal in the 
following 3 clinical categories: mild (5% – 40% of normal); moderate (1% - 5% of 
normal); and, severe (< 1% of normal).
5
 The severity of the disease often dictates its 
clinical presentation and course. Patients with severe hemophilia are prone to 
spontaneous hemorrhage, most typically hemarthosis in the knees, ankles, and elbows. In 
contrast, those with mild hemophilia may only bleed in response to significant tissue 
injury, such as in trauma or surgery.
5-6
  This phenotypic presentation of mild hemophilia 
B explains why the presented patient remained asymptomatic till his index cardiac 
surgery, despite previous minor surgeries. This subclinical Factor IX deficiency remained 
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undiagnosed due to his lack of bleeding symptoms and barely noticeable elevation in the 
partial thromboplastin time, reflecting a mild Factor IX deficiency.
4-6 
 In patients with known hemophilia, the timing of surgery is an important 
consideration. Some authors have suggested that elective surgery should be performed at 
the beginning of the work day and work week.
6-7
 This strategy helps to ensure the 
availability of all staff, an important consideration given that a multidisciplinary team has 
been identified as a key component to ensuring successful outcomes in these patients.
6-8
  
The cornerstone of successful perioperative management for hemophilia B is adequate 
timely replacement of factor IX.
4-5
 Preoperative factor replacement has typically been 
recommended prior to surgery, regardless of whether the patient has mild or severe 
hemophilia B.
7-8
 The recommended target ranges for factor IX during preoperative 
replacement have been designated as 30% - 80% of normal for minor surgery and 50% - 
100% of normal for major surgery.
8-9
    
 During the intraoperative period, the monitoring of Factor IX levels is not 
typically required in the setting of known hemophilia B. A prophylactic intraoperative 
dose based upon recent factor levels has been recommended; the precise dose can be 
calculated with timely hematology consultation.
8-9
 The intraoperative regimen can consist 
of a bolus dose with additional smaller doses depending on the degree of blood loss.
9
  
During the postoperative period, experts have recommended targeting factor IX trough 
levels of 80% - 100% for days 1-3, 60% - 80% on days 4-6, and 40-60% thereafter as 
needed. Furthermore, trough levels should be monitored twice daily during the first 
postoperative week, and thereafter daily as needed.   
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In this case conference, the diagnosis of hemophilia B was Factor IX monitoring and 
targeted therapy were commenced late in the intraoperative period due to the delayed 
diagnosis as outlined.  After the diagnosis was made, factor IX replacement was promptly 
titrated to clinical effect, and measured levels as recommended by hematology 
consultation. 
 A rare but important challenge in hemophilia B patients is the development of 
neutralizing antibodies to recombinant Factor IX that are known as inhibitors.
8-12
 In a 
large database (N = 1172 patients with hemophilia B), only 12 patients (1%) were found 
to develop inhibitors.
10
   Of note, only 86.7% of these patients were confirmed to have 
received treatment for hemophilia.
10
   The incidence of these inhibitors has been reported 
to be in the range of (1-5)%.
11-12
 If these inhibitors are detected, their levels can be 
measured in Bethesda units to stratify clinical risk as follows: low-risk (defined as 
inhibitor levels < 5 Bethesda units/mL); and, high-risk (defined as inhibitor levels > 5 
Bethesda units/mL).
13
 While low-risk patients typically require higher doses of 
recombinant factor IX for effective hemostasis, high-risk patients may require additional 
therapies such as recombinant factor VIIa or prothrombin complex concentrates due to 
their higher resistance to standard therapy.
14-15 
 In 1999 recombinant factor VIIa was approved in the United States for 
hemophiliacs with significant inhibitor levels.
14
 Administration of factor VIIa leads to 
activation of factor X and subsequent thrombin generation.
13
 In a population of 395 
patients with hemophilia (261 surgical patients, 89 dental patients, 45 patients with 
miscellaneous procedures), factor VIIa had an overall efficacy of 84% with only 0.4% 
experiencing thrombotic complications.
14 
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Prothrombin complex concentrates were originally developed for bypassing factor VIII or 
factor IX in hemophilic patients with inhibitors. 
15
 The 4-factor versions contain factors 
II, VII, IX, and X, along with proteins C and S.
15-17
 Thromboembolic complications may 
complicate this therapeutic intervention.
15-17
 In a large meta-analysis with 1,032 patients 
who received PCCs for warfarin reversal, however, the incidence of thromboembolic 
complications was only 1.4%.
16
 
 While not a mainstay therapy for hemophilia, antifibrinolytics such as tranexamic 
acid or aminocaproic acid have been suggested as possible adjuncts.
7, 13
 A recent 
systematic review recently examined the use of antifibrinolytics in oral surgery, but no 
definitive conclusions were drawn due to the limited amount of randomized controlled 
trials.
18
 However, several trials suggested beneficial effects regarding the amount of 
blood loss, number of bleeding episodes, and the requirements for factor concentrates.
18 
 In summary, we highlight a case wherein patient with previously undiagnosed 
mild hemophilia B underwent CABG.  While patients with severe forms of hemophilia 
are likely to have spontaneous bleeding prompting earlier diagnosis, patients with milder 
forms may not manifest until they undergo major surgery. Although this patient 
successfully underwent minor surgeries in the past without complication, his hemophilia 
manifested with severe bleeding during major surgery. His family history was critical in 
raising suspicion for the condition and subsequent factor IX levels confirmed the 
diagnosis. Ultimately, he had a successful outcome due to integrated multidisciplinary 
management. 
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First Expert Commentary  - The Diagnostic Perspective  
(Drs Friess, Lued and Erdoes) 
The authors in this case conference present a case of hemophilia B which was initially 
unrecognized, leading to severe postoperative bleeding in a patient who had undergone 
on-pump CABG. The medical history and the preoperative coagulation profile were 
unremarkable for hemophilia. Due to severe bleeding after weaning from 
cardiopulmonary bypass and heparin reversal with protamine, mediastinal exploration 
was required immediately after initial chest closure. However, no obvious cause for 
bleeding could be found at that time. It wasn’t until contact with the patient’s relatives in 
that a hereditary cause for the significant bleeding was suggested. Focused laboratory 
testing subsequently confirmed the presence of mild hemophilia B, and treatment with 
recombinant factor IX was initiated. 
 Few cases of preoperatively diagnosed hemophilia B have been published. Recent 
reports demonstrate a good clinical outcome for patients with hemophilia B if the 
diagnosis has been established prior to a severe bleeding episode and a proactive 
diagnostic and substitution strategy with recombinant factor IX has been followed.
19-21
 
The World Federation of Hemophilia has produced evidence-based guidelines on the 
management of hemophilia B, and a chapter is dedicated to proactive perioperative 
measures.
5
 
 In the setting of cardiac surgery, cardiac anesthesiologists are often have the 
responsibility for the evaluation of hereditary and acquired bleeding disorders. A 
thorough preoperative assessment may detect a suspicious history of bleeding 
phenomena.
22
 As mild hemophilia B may remain undetected by routine coagulation 
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testing, affected patients lacking obvious bleeding phenomena can be cleared for cardiac 
surgery.
23
 This dilemma underlines the importance of a careful and detailed preoperative 
investigation of the medical history, especially if clinical coagulation is significantly 
impaired in the perioperative course. 
 In retrospect, the slightly prolonged baseline activated clotting time of 131 
seconds in this patient, and the surgeon’s remark that bleeding after skin incision was 
abnormal, might have hinted at the presence of an underlying bleeding disorder. 
Nevertheless, these clues were confounded by the presence of recent therapy with 
clopidogrel, as outlined in the case presentation.  
 After uneventful CABG and weaning from cardiopulmonary bypass, severe 
bleeding developed without obvious surgical etiologies. The heart team examined the 
possibilities, followed up on all the leads, tested their hypotheses, and initiated respective 
therapies. Goal-directed therapy and targeted resuscitation were possible when the 
etiology had been satisfactorily identified. Finding the causative diagnosis, however, 
required sufficient time, which was not readily available in the presented patient given 
the risk of further deterioration due to ongoing bleeding.  
 Apart from obtaining the routine laboratory values as stated in the case 
presentation, point-of-care testing such as viscoelastic hemostatic assays and platelet 
function tests may also be valuable in evaluating unexpected bleeding after 
cardiopulmonary bypass (refer to Figure 2).
24
 Furthermore, if available in the operating 
room after cardiopulmonary bypass, an estimation of the residual heparin level or 
complete neutralization with protamine should be assessed with a point-of-care test. 
Frequently, remaining heparin in the patient’s plasma – after incomplete heparin reversal 
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with protamine or as a consequence of heparin rebound – can lead to a prolonged 
activated clotting time with aggravated bleeding.
25
 In these scenarios, directed point-of-
care testing can distinguish the common causes of prolongations in the activated clotting 
time and unexpected bleeding. During this evaluation process of disordered hemostasis, 
the patient’s temperature, acid-base status, and plasma calcium level should be kept in the 
normal range, as these variables also contribute to an abnormal clotting cascade.  
 The result of the activated clotting time is typically available within minutes. 
Further viscoelastic testing may provide ‘on-line’ diagnostic evaluation of the 
coagulation process to guide targeted therapy.
24
 Unfortunately, current viscoelastic 
testing such as thromboelastography cannot detect mild hemophilia B specifically, 
although many differential diagnoses of severe bleeding are detected readily.
24-27
 Platelet 
function testing also offer an ‘on-line’ analysis and detect pharmacologically impaired 
platelet function. In this presented case, this directed testing could have excluded or 
weakened clopidogrel as the cause for early bleeding, as noticed by the surgeon. 
Laboratory testing, including point-of-care tests, can be ordered and evaluated if severe 
bleeding is expected or encountered.  This sophisticated testing can be conducted towards 
the end of cardiopulmonary bypass to facilitate prediction and management of 
coagulopathy after separation from cardiopulmonary bypass and reversal of heparin.
28-30
  
 The goal of hemostatic testing and management is to diagnose and manage the 
coagulopathy with directed therapy based on test results where possible. Although 
hemophilia B cannot be diagnosed with point-of-care testing alone, many severe 
abnormalities can be revealed and treated in case of ongoing bleeding e.g. 
hypofibrinogenemia and platelet deficiency. In case of hemophilia B – especially if 
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associated with severe perioperative bleeding after cardiac surgery – it is reasonable to 
combine hemostatic therapy consisting of fresh frozen plasma, platelet concentrates, 
factor concentrates and antifibrinolytics in a rational sequence, at least initially while the 
etiology is sought. Subsequently, goal-directed therapy can proceed in a fashion that is 
tailored to clinical findings, laboratory results and institutional protocol.
22
 It remains 
important to titrate therapy in a multimodal fashion, keeping in mind test results and the 
prothrombotic dangers of targeted therapy.
31-34
  
 Anesthesiologists should keep hemophilia in mind as a differential diagnosis in 
the face of severe perioperative bleeding, even if this disease is very rare in both clinical 
routine and the respective literature. Surgery of patients with known hemophilia B is 
already demanding in the elective setting. The emergency setting, as outlined in this case 
presentation, provides even more challenges, since the preparation and planning that was 
possible in the elective setting is not possible.  In terms of this case, we will never know 
whether the diagnosis of hemophilia B would have been possible earlier, but a lesson 
from this challenging case is that investigating the history is key to the successful 
diagnosis and therapy of a bleeding disorder, especially when unexpected.  
Second Expert Commentary  - The Hematology Perspective 
(Dr Miller) 
A review of the current literature reveals that routine preoperative laboratory assessment 
for hemostasis remains controversial.
35
   A thorough history including known hemostatic 
disorders, prior-bleeding events, family bleeding history, and /or relevant medications 
does, however, remain recommended and not controversial.
35
   In our experience, it is 
common for routine laboratory assessment to remain part of the initial work-up for 
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cardiovascular surgery.  The presence of an important subclinical bleeding disorder may 
still defy detection despite these measures, as illustrated in this case conference. 
  The most common types of hemophilia (hemophilia A and hemophilia B) are 
result from X-linked genetic mutations, typically affecting males through maternal 
heritage, resulting in insufficient levels of coagulation factor(s) and thus a inclination for 
bleeding.
5-6
 The risk of major bleeding events is correlated with the percentage of 
deficiency.  Hemophilias are classically categorized based on factor levels as follows: 
mild (5% – 40% of normal); moderate (1% - 5% of normal); and, severe (< 1% of 
normal).
5-6
 While bleeding manifestations typically occur early in life, patients with mild 
forms of hemophilia may not have a notable bleeding event until later in life. Typically, a 
significant stress on coagulation, such as trauma or surgery, results in otherwise 
unexplained bleeding or lack of normal thrombosis.
5 
 It has been estimated that currently there are approximately 400,000 people living 
with hemophilia in the world, although there is concern that many undiagnosed 
hemophiliacs are living in countries with underdeveloped medical care.
5; 36
   Hemophilia 
A (factor VIII deficiency) is the most common, accounting for (80-85)% of all 
hemophilias and occurs in approximately 1:5000 live male births.
6;37
  Hemophilia B 
(factor IX deficiency) occurs in approximately 1:30,000 live male births.
6;37
  Severe 
disease has been estimated in about 65% of Hemophilia A patients and 50% of 
Hemophilia B patients.
37
  Hemophilia can also rarely manifest in live female births, most 
commonly as a mild form in female heterozygotes, however, due to compound 
heterozygosity and complex X chromosome genetics, severe forms can very rarely 
occur.
37 
  
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
17 
Coagulation studies, such as a prothrombin time and partial thromboplastin time are 
commonly evaluated to determine the functional activity of factors.
35; 38-39
 Although these 
tests assess extrinsic and intrinsic coagulation pathways respectively, they are not totally 
representative of in vivo coagulation.
38-39
   These coagulation tests are both time-based  
utilizing the patient’s platelet poor plasma and respective activators to assess the time 
required for a clot to develop.
38
 Prolongations in this setting can indicate either a factor 
deficiency or an inhibitor which can be further distinguished with a mixing study and 
specific factor levels.
38  
In principle, mixing studies that correct with the addition of 
pooled normal plasma to the sample tends to indicate a factor deficiency, whereas lack of 
correction or re-prolonging tends to indicate a factor-specific inhibitor.
38
  
 Relatively recent studies indicate that life expectancy for people with hemophilia 
has increased. 
40-41  
A study performed by the Centers for Disease Control and Prevention 
in the United States reported a life expectancy of at least 64 years, especially since the 
risks of blood-borne infections such as human immunodeficiency virus has significantly 
decreased in the contemporary era.
40
  A 2007 study from the United Kingdom reported a 
median life expectancy of 75 years for people with mild to moderate disease and 63 years 
for those with severe disease when blood-borne infection was excluded.
41  
This improved 
life expectancy for hemophiliacs means that they increasingly will be at risk for age-
related complications such as cardiovascular disease that may require surgical 
intervention. 
 The World Federation of Hemophilia has published recommendations for the 
perioperative management of hemophiliacs.
5 
  The notable recommendations include 
management in a comprehensive hemophilia treatment center, adequate laboratory 
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support for monitoring of clotting factor and inhibitor levels, preoperative assessment 
with inhibitor screening, and adequate supplies of patient specific factor replacement 
products.
5
 The International Society on Thrombosis and Haemostasis has published 
criteria for effective hemostasis for surgical procedures.
42
 In this definition, excellent 
adequacy of hemostasis in hemophiliacs is classified as perioperative blood loss similar 
(within 10%) to non-hemophiliac patients, without unplanned doses of factor or 
bypassing agents needed and  with transfusion of blood products similar to non-
hemophiliac patients.
42
 These guidelines progress from excellent through the grades of  
good and fair to poor adequacy of hemostasis, defined as significant perioperative blood 
loos greater than 50% of expected for non-hemophiliac patients and not explained by 
another medical or surgical complication.
42
   This set of definitions is different to the 
universal definition of perioperative bleeding in adult cardiac surgery that has selected 
clinical end-points such as chest tube output at 12 hours,  allogeneic blood products 
transfused, surgical re-exploration, delayed sternal closure and the need for salvage 
treatment.
43 
 The World Federation of Hemophilia has published recommendations for dosing 
and duration of factor replacement during surgery.
5
 Expert multidisciplinary care with 
experienced subspecialty consultants has been recommended in this setting, as illustrated 
in this case conference.  Overall, the patient in this clinical case scenario had a favorable 
outcome with an undiagnosed bleeding disorder. This case exemplifies the importance of 
detailed past medical and family history to identifying possible unknown bleeding 
disorders in the setting of unexpected major bleeding. 
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Third Expert Commentary  - The Concluding Perspective 
(Drs Ripat and Fabbro) 
The authors present a challenging case of hemophilia B diagnosed in real time during 
cardiac surgery. The case highlights the importance of having a broad differential when 
bleeding is out of proportion to the clinical context. Appropriate diagnosis in patients 
with congenital or acquired bleeding diatheses can facilitate early management changes 
and improve outcomes. This is particularly important given the well-documented 
association between mortality and transfusion in cardiac surgery.
43-45
   Several small 
series of cardiac surgery cases in hemophilia have shown similar transfusion rates to the 
general population.
1-3
 These cases all had pre-established diagnoses and prophylactic 
factor replacement, again emphasizing the importance of early diagnosis in cases similar 
to the one presented in this case conference.  
 With a broad spectrum of factor activity and disease severity, hemophilia patients 
unsurprisingly present with a broad spectrum of clinical manifestations. Diagnosis is 
established readily in children of known carriers or patients who undergo testing 
following a major bleeding event.
45
 When patients with mild factor deficiencies have 
only slight elevations in the partial thromboplastin time, the diagnosis may not be made 
for much of the patient’s life.45 Some reports of hemophilia patients with normal PTT 
values have also been published, further complicating the identification of these 
patients.
23
 Establishing a hemophilia diagnosis in unexpected cases the diagnosis usually 
begins with the workup for an elevated partial thrombolplastin time.
45
 The mainstay of 
this work up is mixing studies and factor assays.
45-46
 The partial thromboplastin time is 
the only routine coagulation test that is typically abnormal in hemophilia.
5-6
 The high 
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normal preoperative partial thromboplastin time in this presented case was an important 
finding in retrospect.  Patients, however, may have an elevated PTT for numerous other 
reasons, including lupus anticoagulant.
46-47
   Consensus algorithms support further work 
up of isolated PTT elevations using mixing tests, as outlined earlier.
37-38
 With over fifteen 
recognized causes of an isolated elevation in the partial thromboplastin time and frequent 
perioperative coagulation testing, detailed investigation in all these settings may be 
impractical.
48
 A more practical approach may be to limit more intensive work ups to 
patients with higher elevations in PTT, patients undergoing major surgery or patients 
undergoing neuraxial or other critical site instrumentation.
46-48
 Emergent surgical 
procedures may provide further barriers to completing the work up. Perhaps more 
importantly, professional society guidelines do not support the use of routine coagulation 
testing, and favor a more selective approach.
5
 The usefulness of routine coagulation 
testing in cardiac surgery is undetermined. Viscoelastography, although incorporated 
more and more into the management of cardiac surgery patients, does not add any 
specific benefit in this patient population.
5; 49 
 Hemophilia management guidelines from the World Federation of Hemophilia are 
widely available for reference.
5-8
 Factor concentrates are administered perioperatively, 
factor VIII or IX for hemophilia A and B respectively, to achieve recommended factor 
levels.
5
 The duration of therapy, dosing and goal levels for factor replacement are based 
on surgery type.
5-8
 The consensus document does not address patients with a suspicious 
clinical presentation and no definitive diagnosis.
5
 Perioperative blood management 
guidelines also fail to address this patient group.
49
 Fresh frozen plasma remains a 
mainstay of bleeding management and is also an alternative therapy for hemophilia 
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patients in limited resource scenarios.
5-8
 Although not used in the United States for 
hemophilia since the 1970’s, fresh frozen plasma has been shown to produce modest 
increases in Factor VIII and IX activity.
5-8
 Factor VIII is the least stable factor once 
thawed, with some estimates of about 67% normal activity after 24 hours.
50
 
Cryoprecipitate, also a mainstay of surgical bleeding management, may be more effective 
than fresh frozen plasma for hemophilia A patients given its factor VIII levels.
5-8
 
Guidelines are also increasingly providing support for the use of prothrombin complex 
concentrates in major bleeding events outside of anticoagulant use.
51
 Prothrombin 
complex concentrate predated high purity factor IX and was the initial factor concentrate 
used in hemophilia patients.
52
 Recombinant activated Factor VII has is also used in 
bleeding cases.
53
 As one of the preferred treatment regimens for hemophilia patients with 
factor inhibitors, factor VII therapy may also help in patients with an unconfirmed 
diagnoses.
53
 Factor inhibitors are a major concern in hemophilia patients, however, less 
likely in a case like the one presented where no long standing history of treatment 
exists.
5-8
   
 In summary, a broad differential for unexpected bleeding rates after cardiac 
surgery is an imperative to achieve a diagnosis and administer effective therapy. In 
situations where patients have mild undiagnosed hemophilia, guideline-directed therapy 
will often manage these patients effectively. This is especially true in cardiac surgery 
patients where multimodal coagulopathy contributes significantly to the clinical picture. 
As seen however, these patients will need continued management following surgery 
stressing the importance of multidisciplinary diagnosis and management. 
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Figure Legends 
 
 
Figure 1: Postoperative Factor IX Levels as Percentage of Normal 
(Note to publisher: this figure was developed completely by the authors - no copyright 
permission required)  
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Figure 2: A Diagnostic Approach to Bleeding in Cardiac Surgery 
(Note to publisher: this figure was developed completely by the authors - no copyright 
permission required)  
 
 
 
 
 
 
 
 
 
 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
24 
References 
 
1. Franchini M. Current management of hemophilia B: recommendations, 
complications and emerging issues.  Expert Rev Haematol 7: 573-581, 2014 
2. Rossi M, Jayaram R, Sayeed R. Do patients with haemophilia undergoing cardiac 
surgery have good surgical outcomes? Interact Cardiovasc Thorac Surg 13:320-
331, 2011 
3. Chamos C, Yates M, Austin S, et al. Minimally invasive aortic valve replacement 
in a patient with severe hemophilia A. J Cardiothorac Vasc Anesth 31:1378-1380, 
2017 
4. Ferraris VA, Boral LI, Cohen AJ, et al. Consensus review of the treatment of 
cardiovascular disease in people with hemophilia A and B. Cardiol Rev 23:53-68, 
2015 
5. Srivastava A, Brewer AK, Mauser-Bunschoten EP, et al. Guidelines for the 
management of hemophilia. Haemophilia 19:e1-47, 2013 
6. Josephson N. The hemophilias and their clinical management. Hematology Am 
Soc Hematol Educ Program 2013:261-267, 2013. 
7. Mensah PK, Gooding R. Surgery in patients with inherited bleeding disorders. 
Anaesthesia. 70:112-120, 2015 
8. Neufeld EJ, Solimeno L, Quon D, et al. Perioperative management of 
haemophilia B: A critical appraisal of the evidence and current practices. 
Haemophilia 23:821-831, 2017 
9. Bhave P, McGiffin D, Shaw J, et al. Guide to performing cardiac surgery in 
patients with hereditary bleeding disorders. J Card Surg 30:61-69, 2015 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
25 
10. Darby SC, Keeling DM, Spooner RJ, et al. The incidence of factor VIII and factor 
IX inhibitors in the hemophilia population of the UK and their effect on 
subsequent mortality, 1977-1999.  J Thromb Haemost 2:1047-1054, 2004 
11. DiMichele D. Inhibitor development in haemophilia B: an orphan disease in need 
of attention. Brit J Haem 138:305-315, 2007 
12. Gomez K, Klamroth R, Mahlangu J, et al. Key issues in inhibitor management in 
patients with haemophilia. Blood Transf. 12 (Suppl 1):s319-s329, 2014 
13. Shah UJ, Narayanan M, Graham Smith J. Anaesthetic considerations in patients 
with inherited disorders of coagulation. Cont Educ Anaesth Crit Care Pain 15:26-
31, 2015 
14. Valentino LA, Cooper DL, Goldstein B. Surgical experience with rFVIIa 
(NovoSeven) in congenital haemophilia A and B patients with inhibitors to 
factors VIII or IX. Haemophilia 17:579-589, 2011 
15. Ragni MV: The old and new: PCCs, VIIa, and long-lasting clotting factors for 
hemophilia and other bleeding disorders. Hematology Am Soc Hematol Educ 
Prog 2013:44-51, 2013 
16. Tanaka KA, Esper S, Bolliger D: Perioperative factor concentrate therapy. Brit J 
Anaesth 111 (Suppl 1):i35-49, 2013 
17. Smith MM, Ashkhmina E, Brinkman NJ, et al.  Perioperative use of coagulation 
factor concentrates in patients undergoing cardiac surgery.  J Cardiothorac Vasc 
Anesth 31: 1810-1819, 2017 
 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
26 
18. van Galen KP, Engelen ET, Mauser-Bunschoten EP, et al. Antifibrinolytic 
therapy for preventing oral bleeding in patients with haemophilia or Von 
Willebrand disease undergoing minor oral surgery or dental extractions.  
Cochrane Database Syst Rev.Cd011385, 2015 
19. Krakow EF, Walker I, Lamy A, et al.  Cardiac surgery in patients with 
 haemophilia B: a case report and review of the literature. Haemophilia 
 15:108–113, 2009 
20. Takeyama M, Nogami K, Shida Y, et al. Successful haemostatic management of 
 replacement of the ascending aorta for type A acute aortic dissection in a patient 
 with mild haemophilia B. Haemophilia 2016 [Epub ahead of print] 
21.  Thankachen R, George B, Shukla V, et al. Aortic and mitral valve replacement in 
 a patient with hemophilia B. Asian Cardiovasc Thorac Ann 15:526–527, 2007 
22.  Mellin-Olsen J, Staender S, Whitaker DK, et al. The Helsinki declaration on  
 patient safety in anaesthesiology. Eur J Anaesthesiol 27:592–597, 2010 
23.  Park CH, Seo JY, Kim HJ, et al. A diagnostic challenge: mild hemophilia B 
 with normal activated partial thromboplastin time. Blood Coagul Fibrinolysis 
 21:368–371, 2010 
24.   Fabbro M 2
nd
, Winkler Am, Levy JH.  Technology: is there sufficient evidence to 
 change practice in point-of-care management of coagulopathy?  J Cardiothorac 
 Vasc Anesth 31: 1849-1856, 2017 
25.  Galeone A, Rotumno C, Guida P, et al.  Monitoring incomplete heparin reversal 
 and heparin rebound after cardiac surgery. J Cardiothorac Vasc Anesth 27: 853-
 858, 2013 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
27 
26. Nummi V, Jouppila A, Lassila R. Monitoring once-weekly recombinant factor IX 
prophylaxis in hemophilia B with thrombin generation assay and factor IX activity. 
Int J Lab Hematol 39:359–368, 2017 
27. Kozek-Langenecker SA, Ahmed AB, Afshari A, et al. Management of severe 
perioperative bleeding: guidelines from the European Society of Anaesthesiology: 
first update 2016. Eur J Anaesthesiol 34:332–395, 2017 
28. Solomon C, Baryshnikova E, Tripodi A, et al. Fibrinogen measurement in cardiac 
surgery with cardiopulmonary bypass: analysis of repeatability and agreement of 
Clauss method within and between six different laboratories. Thromb Haemost 
112:109–117, 2014 
29.  Erdoes G, Gerster G, Colucci G, et al. Prediction of post-weaning fibrinogen status 
during cardiopulmonary bypass: an observational study in 110 patients. PLoS One 
10: e0126692, 2015 
30. Olde Engberink RH, Kuiper GJ, Wetzels RJ, et al. Rapid and correct prediction of 
thrombocytopenia and hypofibrinogenemia with rotational thromboelastometry in 
cardiac surgery. J Cardiothorac Vasc Anesth 28:210–216, 2014 
31. Görlinger K, Shore-Lesserson L, Dirkmann D, et al. Management of hemorrhage in 
cardiothoracic surgery. J Cardiothorac Vasc Anesth 27:S20–S34, 2013 
32. Batty P, Honke A, Bowles L, et al. Ongoing risk of thrombosis with factor XI 
concentrate: 5 years experience in two centers. Haemophilia 21:490–495, 2015 
 
 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
28 
33. Koster A, Meyer-Jark T, Schirmer U, et al. Fulminant intraoperative right heart and 
pulmonary artery thrombosis following prothrombin complex concentrate infusion 
after complex open heart surgery with cardiopulmonary bypass. A case report AA 
Case Rep 2:89–91, 2014 
34. Harper PC, Smith MM, Brinkman NJ, et al. Outcomes following three-factor 
inactive prothrombin complex concentrate versus recombinant activated Factor VII 
administration during cardiac surgery. J Cardiothorac Vasc Anesth 32:151-157, 2018 
35.  Chee YL, Crawford JC, Watson HG, et al. Guidelines on the assessment of bleeding 
risk prior to surgery or invasive procedures. British Committee for Standards in 
Haematology. Br J Haematol. 140:496-504, 2008 
36. Shetty S: Haemophilia - diagnosis and management challenges. Mol Cytogenet. 
7:I44, 2014 
37. Carcao MD: The diagnosis and management of congenital hemophilia. Semin 
Thromb Hemost. 38:727-734, 2012 
38.  Winter WE, Flax SD, Harris  NS.  Coagulation testing in the core laboratory.  Lab 
Med 48: 295-313, 2017 
39.  Sevenet PD, Depasse F.  Clot waveform analysis: where do we stand in 2017?  Int J 
Lab hematol 39: 561-568, 2017 
40. Soucie JM, Nuss R, Evatt B, et al. Mortality among males with hemophilia: relations 
with source of medical care. The Hemophilia Surveillance System Project 
Investigators. Blood 96:437-442, 2000 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
29 
41. Darby SC, Kan SW, Spooner RJ, et al.: Mortality rates, life expectancy, and causes 
of death in people with hemophilia A or B in the United Kingdom who were not 
infected with HIV. Blood. 110:815-825, 2007 
42. Schulman S, Angeras U, Bergqvist D, et al.  Definition of major bleeding in clinical 
investigations of antihemostatic medicinal products in surgical patients.  J Thromb 
Haemost 8: 202-204, 2010 
43.  Dyke C, Aronson S, Dietrich W, et al.  Universal definition of perioperative bleeding 
in adult cardiac surgery.  J Thorac Cardiovasc Surg 147: 1458-1463, 2014 
44. Murphy GJ, Reeves BC, Rogers CA, et al. Increased mortality, postoperative 
morbidity, and cost after red blood cell transfusion in patients having cardiac 
surgery. Circulation 116:2544-2552, 2007 
45.  Fijnvandraat K, Cnossen MH, Leebeek FW, et al. Diagnosis and management of 
haemophilia. Brit Med J 344:1-5, 2012 
46. Kitchens CS. To bleed or not to bleed - is that the question for the PTT? J Thromb 
Haemost 3:2607-2611, 2005 
47.Tcherniantchouk O, Laposata M, Marques MB. The isolated prolonged PTT. Am J 
Hematol 88:82-85, 2013 
48.
 
Van Veen JJ, Spahn DR, Makris M. Routine preoperative coagulation tests: an 
outdated practice? Brit J Anaesth 106:1-3, 2011 
49.
 
Ferraris VA, Brown JR, Despotis GJ, et al. 2011 update to the Society of Thoracic 
Surgeons and the Society of Cardiovascular Anesthesiologists blood conservation 
clinical practice guidelines. Ann Thorac Surg 91:944-982, 2011 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
30 
50.
 
Milam JD, Buzzurro CJ, Austin SF, et al. Stability of factors V and VIII in thawed 
fresh frozen plasma units. Transfusion 20:546-548, 1980 
51.
 
Rossaint R, Bouillon B, Cerny V, et al. The European guideline on management of 
major bleeding and coagulopathy following trauma (fourth version). Crit Care 
20:100, 2016 
52. Franchini M, Lippi G. Prothrombin complex concentrates: an update. Blood 
Transfusion. 8:149, 2010 
53.
 
Kenet G, Lubetsky A, Luboshitz J, et al. A new approach to treatment of bleeding 
episodes in young hemophilia patients: a single bolus megadose of recombinant 
activated factor VII (NovoSeven®). J Thromb Haemostas 1:450-455, 2003
 
 
 
 
 
 
 
